Amgen
Stock Forecast, Prediction & Price Target
Amgen (AMGN) stock Price Target by analysts
Amgen (AMGN) stock Price Target by analysts
Average Price Target
$338.63
Potential upside: 13.86%
Amgen price prediction
What is Amgen stock analysts` prediction?
Amgen stock forecast: Based on 8 Wall Street analysts` predicted price targets for Amgen in the last 3 months, the avarage price target is $338.63, with a high forecast of $NaN. The average price target represents a 13.86% change from the last price of $297.4.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Amgen stock Price Target by analysts
Full breakdown of analysts given Amgen price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Michael Yee Jefferies | 50% 1/2 | 10 months ago | $380 27.77% upside | $298.84 | StreetInsider | Previous targets (1) |
Olivia Brayer Cantor Fitzgerald | 0% 0/1 | 10 months ago | $405 36.18% upside | $298.84 | StreetInsider | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/3 | 11 months ago | $319 7.26% upside | $316.74 | TheFly | Previous targets (2) |
Salveen Richter Goldman Sachs | 50% 1/2 | 11 months ago | $369 24.07% upside | $325.09 | StreetInsider | Previous targets (1) |
Carter Gould Barclays | 50% 2/4 | 11 months ago | $315 5.91% upside | $319.66 | TheFly | Previous targets (3) |
Christopher Raymond Raymond James | 50% 1/2 | 11 months ago | $344 15.66% upside | $330.92 | StreetInsider | Previous targets (1) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | 11 months ago | $362 21.72% upside | $330.92 | StreetInsider | Previous targets (2) |
Brian Skorney Robert W. Baird | 0% 0/1 | 11 months ago | $215 -27.70% downside | $330.92 | StreetInsider | Previous targets (0) |
Mohit Bansal Wells Fargo | 25% 1/4 | about 1 year ago | $335 12.64% upside | $328.95 | TheFly | Previous targets (3) |
Terence Flynn Morgan Stanley | 0% 0/3 | about 1 year ago | $303 1.88% upside | $330.79 | Benzinga | Previous targets (2) |
Gregory Renza RBC Capital | 0% 0/1 | about 1 year ago | $332 11.63% upside | $298.71 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 66.67% 2/3 | over 1 year ago | $380 27.77% upside | $312.32 | StreetInsider | Previous targets (2) |
Salim Syed Mizuho Securities | 50% 1/2 | over 1 year ago | $235 -20.98% downside | $307.31 | StreetInsider | Previous targets (1) |
Carter Gould Barclays | 50% 2/4 | over 1 year ago | $300 0.87% upside | $278.39 | StreetInsider | Previous targets (3) |
Colin Bristow UBS | 50% 1/2 | over 1 year ago | $307 3.22% upside | $278.39 | StreetInsider | Previous targets (1) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | over 1 year ago | $355 19.36% upside | $278.39 | StreetInsider | Previous targets (2) |
Terence Flynn Morgan Stanley | 0% 0/3 | over 1 year ago | $310 4.23% upside | $315.19 | TheFly | Previous targets (2) |
Mohit Bansal Wells Fargo | 25% 1/4 | over 1 year ago | $320 7.59% upside | $265.11 | StreetInsider | Previous targets (3) |
Jay Olson Oppenheimer | 66.67% 2/3 | almost 2 years ago | $280 -5.85% downside | $260.31 | Benzinga | Previous targets (2) |
Michael Yee Jefferies | 50% 1/2 | almost 2 years ago | $310 4.23% upside | $260.31 | Benzinga | Previous targets (1) |
Mohit Bansal Wells Fargo | 25% 1/4 | over 2 years ago | $265 -10.89% downside | $251.08 | Benzinga | Previous targets (3) |
Mohit Bansal Wells Fargo | 25% 1/4 | over 2 years ago | $275 -7.53% downside | $228.84 | Benzinga | Previous targets (3) |
Unknown Leerink Partners | N/A | over 2 years ago | $267 -10.22% downside | $246.41 | Benzinga | N/A |
Unknown BMO Capital | N/A | over 2 years ago | $253 -14.92% downside | $252.4 | Benzinga | N/A |
Unknown Cowen & Co. | N/A | over 2 years ago | $289 -2.82% downside | $243.47 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $275 -7.53% downside | $243.11 | Benzinga | N/A |
Unknown Oppenheimer | N/A | over 2 years ago | $294 -1.14% downside | $243.8 | Benzinga | N/A |
Unknown RBC Capital | N/A | over 2 years ago | $258 -13.24% downside | $242.92 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $285 -4.16% downside | $260.67 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $282 -5.17% downside | $266.26 | Benzinga | N/A |
Unknown Piper Sandler | N/A | over 2 years ago | $299 0.53% upside | $276.78 | Benzinga | N/A |
Unknown Oppenheimer | N/A | over 2 years ago | $310 4.23% upside | $285.59 | Benzinga | N/A |
Christopher Raymond Raymond James | 50% 1/2 | over 2 years ago | $297 -0.13% downside | $285.73 | TheFly | Previous targets (1) |
Unknown Credit Suisse | N/A | almost 3 years ago | $240 -19.30% downside | $287.3 | Benzinga | N/A |
Carter Gould Barclays | 50% 2/4 | almost 3 years ago | $234 -21.31% downside | $273.81 | TheFly | Previous targets (3) |
Unknown Atlantic Equities | N/A | about 3 years ago | $182 -38.80% downside | $247.29 | Benzinga | N/A |
Unknown RBC Capital | N/A | about 3 years ago | $236 -20.64% downside | $246.98 | Benzinga | N/A |
Unknown Piper Sandler | N/A | about 3 years ago | $265 -10.89% downside | $246.98 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $253 -14.92% downside | $247.87 | Benzinga | N/A |
Jay Olson Oppenheimer | 66.67% 2/3 | over 3 years ago | $290 -2.48% downside | $248.94 | Pulse 2.0 | Previous targets (2) |
Salim Syed Mizuho Securities | 50% 1/2 | over 3 years ago | $208 -30.06% downside | $239.24 | Pulse 2.0 | Previous targets (1) |
Evan Seigerman BMO Capital | 100% 1/1 | over 3 years ago | $243 -18.29% downside | $238.13 | Pulse 2.0 | Previous targets (0) |
Carter Gould Barclays | 50% 2/4 | over 3 years ago | $236 -20.64% downside | $254.02 | Pulse 2.0 | Previous targets (3) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | over 3 years ago | $240 -19.30% downside | $220.77 | Pulse 2.0 | Previous targets (2) |
Kennen MacKay RBC Capital | 100% 1/1 | over 3 years ago | $218 -26.69% downside | $238.96 | TipRanks Contributor | Previous targets (0) |
Christopher Raymond Piper Sandler | 100% 1/1 | over 3 years ago | $255 -14.25% downside | $238.96 | TheFly | Previous targets (0) |
Colin Bristow UBS | 50% 1/2 | over 3 years ago | $232 -21.99% downside | $238.96 | StreetInsider | Previous targets (1) |
Yaron Werber Cowen & Co. | 100% 1/1 | over 3 years ago | $275 -7.53% downside | $222.1 | StreetInsider | Previous targets (0) |
Geoff Meacham Bank of America Securities | 100% 1/1 | over 3 years ago | $255 -14.25% downside | $223.23 | MarketWatch | Previous targets (0) |
Salveen Richter Goldman Sachs | 50% 1/2 | over 3 years ago | $258 -13.24% downside | $207.02 | TheFly | Previous targets (1) |
Amgen Financial Estimates
Amgen Revenue Estimates
Amgen EBITDA Estimates
Amgen Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $25.97B N/A | $26.32B 1.32% | $28.19B 7.09% | Avg: $33.96B Low: $33.07B High: $34.85B avg. 20.49% | Avg: $34.71B Low: $33.76B High: $35.74B avg. 2.19% | Avg: $34.99B Low: $34.04B High: $36.04B avg. 0.82% | Avg: $35.29B Low: $34.32B High: $36.34B avg. 0.83% |
Net Income
% change YoY
| $5.89B N/A | $6.55B 11.18% | $6.71B 2.51% | Avg: $6.20B Low: $5.00B High: $9.82B avg. -7.57% | Avg: $6.87B Low: $5.40B High: $10.94B avg. 10.75% | Avg: $11.59B Low: $11.18B High: $12.04B avg. 68.61% | Avg: $11.80B Low: $11.38B High: $12.26B avg. 1.85% |
EBITDA
% change YoY
| $9.40B N/A | $8.75B -6.92% | $14.70B 67.98% | Avg: $13.82B Low: $13.46B High: $14.18B avg. -5.95% | Avg: $14.13B Low: $13.74B High: $14.55B avg. 2.19% | Avg: $14.24B Low: $13.85B High: $14.67B avg. 0.82% | Avg: $14.36B Low: $13.97B High: $14.79B avg. 0.83% |
EPS
% change YoY
| $10.34 N/A | $12.18 17.79% | $12.56 3.11% | Avg: $12.34 Low: $9.31 High: $18.27 avg. -1.74% | Avg: $13.62 Low: $10.04 High: $20.34 avg. 10.35% | Avg: $21.55 Low: $20.78 High: $22.39 avg. 58.23% | Avg: $21.95 Low: $21.17 High: $22.8 avg. 1.85% |
Operating Expenses
% change YoY
| $10.38B N/A | $10.35B -0.28% | $11.87B 14.75% | Avg: $7.31B Low: $7.12B High: $7.51B avg. -38.38% | Avg: $7.47B Low: $7.27B High: $7.70B avg. 2.19% | Avg: $7.54B Low: $7.33B High: $7.76B avg. 0.82% | Avg: $7.60B Low: $7.39B High: $7.83B avg. 0.83% |
FAQ
What is Amgen stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 18.41% in 2025-2028.
We have gathered data from 16 analysts. Their low estimate is 5.00B, average is 6.20B and high is 9.82B.
What is Amgen stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 6.08% in 2025-2028.
We have gathered data from 21 analysts. Their low revenue estimate is $33.07B, average is $33.96B and high is $34.85B.
What is Amgen stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 17.17% in 2025-2028.
We have gathered data from 16 analysts. Their low earnings per share estimate is $9.31, average is $12.34 and high is $18.27.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Amgen stock. The most successful analyst is Michael Yee whose win rate is 50%. He has correctly predicted 1/2 price targets.